Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia
暂无分享,去创建一个
[1] A. O’Garra,et al. CD8+ T cells control Th2‐driven pathology during pulmonary respiratory syncytial virus infection , 1997, European journal of immunology.
[2] T. Braciale,et al. Virus-specific CD8+ T Lymphocytes Downregulate T Helper Cell Type 2 Cytokine Secretion and Pulmonary Eosinophilia during Experimental Murine Respiratory Syncytial Virus Infection , 1997, The Journal of experimental medicine.
[3] P. Openshaw,et al. IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness. , 1997, Journal of immunology.
[4] R. Garofalo,et al. Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells. , 1997, The Journal of infectious diseases.
[5] T. Braciale,et al. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection , 1997, Journal of virology.
[6] R. C. Veen. Immunogenicity of JHM virus proteins: characterization of a CD4+ T cell epitope on nucleocapsid protein which induces different T-helper cell subsets. , 1996 .
[7] A. O’Garra,et al. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. , 1996, The Journal of general virology.
[8] M. Trudel,et al. Evidence that the amino acid region 124-203 of glycoprotein G from the respiratory syncytial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection. , 1995, Antiviral research.
[9] T. Williams,et al. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo , 1995, The Journal of experimental medicine.
[10] F. Schödel,et al. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent , 1995, Journal of virology.
[11] N. Day,et al. Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[12] S. Southwood,et al. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo , 1995, The Journal of experimental medicine.
[13] B. Björkstén,et al. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. , 1995, Pediatrics.
[14] J. Orange,et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids , 1995, The Journal of experimental medicine.
[15] P. Openshaw,et al. Distinct types of lung disease caused by functional subsets of antiviral T cells , 1994, The Journal of experimental medicine.
[16] B. Graham,et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. , 1993, Journal of immunology.
[17] P. Openshaw,et al. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. , 1993, Journal of immunology.
[18] J. Melero,et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. , 1992, The Journal of general virology.
[19] P. Openshaw,et al. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells , 1992, Clinical and experimental immunology.
[20] P. Openshaw,et al. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. , 1992, International immunology.
[21] L. A. Bunton,et al. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. , 1991, The Journal of clinical investigation.
[22] B. García-Barreno,et al. Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. , 1990, The EMBO journal.
[23] S. Levine,et al. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. , 1987, The Journal of general virology.
[24] R. Pemberton,et al. Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. , 1987, The Journal of general virology.
[25] L. A. Ball,et al. Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice , 1987, Journal of virology.
[26] L. A. Ball,et al. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge , 1986, Journal of virology.
[27] G. Meiklejohn,et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. , 1969, American journal of epidemiology.
[28] R. Chanock,et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. , 1969, American journal of epidemiology.
[29] R. Chanock,et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.
[30] E. H. Lennette,et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. , 1969, American journal of epidemiology.
[31] R. C. van der Veen. Immunogenicity of JHM virus proteins: characterization of a CD4+ T cell epitope on nucleocapsid protein which induces different T-helper cell subsets. , 1996, Virology.
[32] L. J. Anderson,et al. Protective and disease-enhancing immune responses to respiratory syncytial virus. , 1995, The Journal of infectious diseases.
[33] P. Openshaw,et al. Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. , 1993, Vaccine.